MicroPort Scientific : ® CardioFlow Attends 2017 PCR-CIT China Chengdu Valves

Chengdu, China - On November 25, MicroPort Shanghai CardioFlow Medtech Co., Ltd. ('MicroPort CardioFlow') attended the 2017 PCR-CIT China Chengdu Valves and displayed its VitaFlow™ Transcatheter Aortic Valve and Delivery System ('VitaFlow™'). The conference was hosted by PCR, CIT, and Huaxi Hospital of Sichuan University.

In the session of transcatheter aortic valve innovative treatment, the representative of MicroPort CardioFlow delivered a speech about 'Innovative Solution of MicroPort: to Solve the Unmet needs,' sharing MicroPort CardioFlow's understanding in the unmet needs and proposed solutions. According to the speech, there are three keys factors in technical improvement of TAVI treatment: reducing the occurrence rate of postoperative complications, solving the clinical challenges in special anatomic conditions, and ensuring the long-term efficacy. With its innovative skirt design, VitaFlow™ can effectively reduce the paravalvular leak. It keeps its outer diameter at 16F18F while reinforcing its radial force, which can skillfully expand calcified leaflets. The excellent clinical outcome of VitaFlow™ has won recognition from industry peers. Moreover, the device has achieved breakthrough in coping with bicuspid aortic valve challenge - there has no significant difference of clinical results between 41 bicuspid aortic valve patients (41/110) and other non-bicuspid patients who are enrolled in Chinese FDA clinical trial. Afterwards, MicroPort CardioFlow introduced the upcoming second-generation of VitaFlow™. Its added recapturable function will greatly lower the difficulty of positioning during the procedure, which effectively improve the success rate and facilitate physicians in operation. The second generation of VitaFlow™ product has many features including direct access, omnidirectional navigation, and reinforced compatibility which would help reduce vascular complication remarkably. In the end, the representative of MicroPort CardioFlow presented on the development trend of future products. MicroPort CardioFlow will continue to innovate and increase product offerings based on the unmet clinical needs to provide comprehensive solutions for physicians.

In the session of valve on the second day, Professor Darren Mylott, a renowned cardiologist from Ireland-based Galway University Hospital, made a presentation on the design features and typical cases of MicroPort VitaFlow™. Professor Darren Mylott shared his clinical experience in VitaFlow™ and introduced its advantages, clinical follow-up, as well as its second-generation recapturable device. In the following debate session of 'Should we simplify TAVI procedure in China now?' Professor Darren Mylott once again mentioned the advantages of the second-generation VitaFlow™ in simplifying operation procedures. At the same time, Professor Yundai Chen of Chinese PLA General Hospital and Professor Xiangqing Kong of Nanjing First Hospital of Nanjing Medical University both spoke highly of the excellent clinical performance of VitaFlow™ in patients with heavy calcified leaflets and bicuspid aortic valve, and they said they looked forward to the durability test of the device.

During the conference, many renowned experts visited MicroPort CardioFlow booth to learn about the design rationale of VitaFlow™ and they highly recognized its innovative design and excellent clinical performance. Up to date, VitaFlow™ has completed one-year clinical follow-up in China. In August 2016, VitaFlow™ was granted the Green-Path by the China Food and Drug Administration ('CFDA'), a special fast-track procedure for innovative medical devices to gain CFDA approval, which will significantly shorten the approval time for VitaFlow™. VitaFlow™ is expected to gain CFDA approval in 2018.

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:

Amanda Zhang Corporate Culture & Public Relations Director Shanghai MicroPort Medical (Group) Co., Ltd. (HQ) Tel: [phone]-6989 Email: [e-mail]